Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [RNA_SEQ]

ABSTRACT: MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [RNA_SEQ]

PROVIDER: PRJNA748672 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR15207414.fastq.gz	Fastqsanger.gz
	SRR15207415.fastq.gz	Fastqsanger.gz
	SRR15207416.fastq.gz	Fastqsanger.gz
	SRR15207417.fastq.gz	Fastqsanger.gz
	SRR15207418.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells

Project description:MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells

| PRJNA750650 | ENA

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells

Project description:MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells

| PRJNA748665 | ENA

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [CHIP_SEQ]

Project description:MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [CHIP_SEQ]

| PRJNA748673 | ENA

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [RNA_SEQ]

Project description:Glucocorticoids (GCs) exert potent anti-inflammatory effects in immune cells through the glucocorticoid receptor (GR). Dendritic cells (DCs), central actors for coordinating immune responses, acquire tolerogenic properties in response to GCs. Tolerogenic DCs (tolDCs) have emerged as a potential treatment for different inflammatory diseases. To date, the underlying cell type-specific regulatory mechanisms orchestrating GC-mediated acquisition of immunosuppressive properties remain poorly understood. In this study, we investigated the transcriptomic and epigenomic remodeling associated with differentiation to DCs in the presence of GCs. Our analysis demonstrates a major role of MAFB in this process, in synergy with GR. Both GR and MAFB interact with methylcytosine dioxygenase TET2 and bind to genomic loci that undergo specific demethylation in tolDCs. We also show that the role of MAFB is more extensive, binding to thousands of genomic loci in tolDCs. Finally, MAFB knockdown erases the tolerogenic properties of tolDCs and reverts the specific DNA demethylation and gene upregulation. The preeminent role of MAFB is also demonstrated in vivo for myeloid cells from synovium in rheumatoid arthritis following GC treatment. These results support that, once directly activated by GR, MAFB takes over the main roles to orchestrate the epigenomic and transcriptomic remodelling that define the tolerogenic phenotype.

2021-11-11 | GSE180540 | GEO

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [expression array]

Project description:MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [expression array]

| PRJNA748606 | ENA

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [Methylation_1 array]

Project description:MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [Methylation_1 array]

| PRJNA748619 | ENA

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [Methylation_2 array]

Project description:MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [Methylation_2 array]

| PRJNA748620 | ENA

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells

Project description:Glucocorticoids (GCs) exert potent anti-inflammatory effects in innate immune cells through the glucocorticoid receptor (GR). Dendritic cells (DCs), central actors for coordinating immune responses, acquire tolerogenic properties in response to GCs. Tolerogenic DCs (tolDCs) have emerged as a potential treatment for different inflammatory diseases. To date, the underlying cell type-specific regulatory mechanisms orchestrating GC-mediated acquisition of immunosuppressive properties remain poorly understood. In this study, we investigated the transcriptomic and epigenomic remodeling associated with differentiation to DCs in the presence of GCs. Our analysis demonstrates a major role of MAFB in this process, in synergy with GR. Both GR and MAFB interact with methylcytosine dioxygenase TET2 and bind to genomic loci that undergo specific demethylation in tolDCs. We also show that the role of MAFB is more extensive, binding to thousands of genomic loci in tolDCs. Finally, MAFB knockdown erases the tolerogenic properties of tolDCs and reverts the specific DNA demethylation and gene upregulation. The preeminent role of MAFB is also demonstrated in vivo for myeloid cells from synovium in rheumatoid arthritis following GC treatment. These results support that, once directly activated by GR, MAFB takes over the main roles to orchestrate the epigenomic and transcriptomic remodelling that define the tolerogenic phenotype.

2021-11-11 | GSE181082 | GEO

MAFB surrogates the glucocorticoid receptor ability to induce tolerogenesis in dendritic cells [CHIP_SEQ]

2021-11-11 | GSE180539 | GEO